2016
Sexual dimorphism of liver metastasis by murine pancreatic neuroendocrine tumors is affected by expression of complement C5
Contractor T, Kobayashi S, da Silva E, Clausen R, Chan C, Vosburgh E, Tang LH, Levine AJ, Harris CR. Sexual dimorphism of liver metastasis by murine pancreatic neuroendocrine tumors is affected by expression of complement C5. Oncotarget 2016, 7: 30585-30596. PMID: 27105526, PMCID: PMC5058703, DOI: 10.18632/oncotarget.8874.Peer-Reviewed Original ResearchConceptsComplement C5Liver metastasesAdvanced tumorsNeuroendocrine tumorsMouse modelSmall primary tumorsPancreatic neuroendocrine tumorsTypes of tumorsSmall molecule antagonistsIntratumoral levelsPrimary tumorMale miceComplement C5aMetastasisTumorsMolecule antagonistsMiceHigh frequencySexual dimorphismHuman diseasesMalesFirst reportCD88CD68PMX53
2014
High-throughput Image Analysis of Tumor Spheroids: A User-friendly Software Application to Measure the Size of Spheroids Automatically and Accurately
Chen W, Wong C, Vosburgh E, Levine AJ, Foran DJ, Xu EY. High-throughput Image Analysis of Tumor Spheroids: A User-friendly Software Application to Measure the Size of Spheroids Automatically and Accurately. Journal Of Visualized Experiments 2014, 51639. PMID: 25046278, PMCID: PMC4212916, DOI: 10.3791/51639.Peer-Reviewed Original ResearchConceptsGraphical user interfaceLarge-scale image analysisImage analysis applicationsUser-friendly software applicationFree image analysis softwareImage analysisActive contour algorithmHigh-throughput image analysisHigh-throughput computationTime-consuming processUser interfaceSoftware applicationsImage analysis softwareAnalysis applicationsNumber of applicationsUneven illuminationQuality control workflowContour algorithmAnalysis softwareQuality imagesNoisy backgroundSoftwareAnalysis processImagesEasy quality control
2012
Human Neuroendocrine Tumor Cell Lines as a Three-Dimensional Model for the Study of Human Neuroendocrine Tumor Therapy
Wong C, Vosburgh E, Levine AJ, Cong L, Xu EY. Human Neuroendocrine Tumor Cell Lines as a Three-Dimensional Model for the Study of Human Neuroendocrine Tumor Therapy. Journal Of Visualized Experiments 2012, 4218. PMID: 22929519, PMCID: PMC3486771, DOI: 10.3791/4218.Peer-Reviewed Original ResearchConceptsNeuroendocrine tumorsNET cell linesDrug treatmentCell linesMetastatic neuroendocrine tumorsMinority of patientsHuman neuroendocrine tumor cell linesNeuroendocrine Tumor TherapyNew therapeutic targetsBiology of NETsNeuroendocrine tumor cell linesSingle-drug effectsHuman NET cell linesLocalized diseaseNET patientsSurvival benefitSystemic therapyRare tumorDrug effectsImmunohistochemical techniquesTherapeutic targetAnimal modelsNET biologyTumor cell linesHuman malignanciesHeat shock protein 90 is a promising target for effective growth inhibition of gastrointestinal neuroendocrine tumors.
Gloesenkamp C, Nitzsche B, Lim A, Normant E, Vosburgh E, Schrader M, Ocker M, Scherübl H, Höpfner M. Heat shock protein 90 is a promising target for effective growth inhibition of gastrointestinal neuroendocrine tumors. International Journal Of Oncology 2012, 40: 1659-67. PMID: 22246317, DOI: 10.3892/ijo.2012.1328.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsApoptosisBenzoquinonesCell Cycle CheckpointsCell Line, TumorCell MovementCell ProliferationChick EmbryoChorioallantoic MembraneDose-Response Relationship, DrugFlow CytometryGastrointestinal NeoplasmsGene Expression ProfilingGene Expression Regulation, NeoplasticHSP90 Heat-Shock ProteinsHumansLactams, MacrocyclicNeuroendocrine TumorsPhosphatidylinositol 3-KinaseProtein Kinase InhibitorsProto-Oncogene Proteins c-aktReceptor, IGF Type 1Signal TransductionTOR Serine-Threonine KinasesConceptsShock protein 90IGF-1 receptorIPI-504Protein 90GEP-NETsNeuroendocrine tumorsHsp90 inhibitor IPI-504Heat shock protein 90Antiproliferative effectsGEP-NET cellsDose-dependent growth inhibitionGEP-NET treatmentPI3K/AKT/mTOR pathwayGastrointestinal neuroendocrine tumorsGastroenteropancreatic neuroendocrine tumorsAKT/mTOR pathwayCancer gene expressionAdditive antiproliferative effectsCell cycle arrestInnovative therapeutic approachesTyrosine kinase inhibitionGrowth inhibitionMechanism of actionGene expressionHsp90 inhibition
2010
A pilot genome-wide association study shows genomic variants enriched in the non-tumor cells of patients with well-differentiated neuroendocrine tumors of the ileum
Walsh KM, Choi M, Oberg K, Kulke MH, Yao JC, Wu C, Jurkiewicz M, Hsu LI, Hooshmand SM, Hassan M, Janson ET, Cunningham JL, Vosburgh E, Sackler RS, Lifton RP, DeWan AT, Hoh J. A pilot genome-wide association study shows genomic variants enriched in the non-tumor cells of patients with well-differentiated neuroendocrine tumors of the ileum. Endocrine Related Cancer 2010, 18: 171-180. PMID: 21139019, PMCID: PMC3221459, DOI: 10.1677/erc-10-0248.Peer-Reviewed Original ResearchMeSH KeywordsCase-Control StudiesCell DifferentiationCellsDNA Copy Number VariationsFemaleGenetic VariationGenome-Wide Association StudyHumansIleal NeoplasmsMaleMeta-Analysis as TopicMicroarray AnalysisNeoplasm StagingNeuroendocrine TumorsPilot ProjectsPolymorphism, Single NucleotideReview Literature as TopicConceptsLoss of heterozygosityDana-Farber Cancer InstituteTumor cellsMD Anderson Cancer CenterCarcinoid tumor cellsUppsala University HospitalPopulation-based controlsAnderson Cancer CenterCopy number variantsBonferroni-corrected levelBlood-derived DNACarcinoid cancerReal-time quantitative PCRCancer CenterNeuroendocrine tumorsUniversity HospitalNon-tumor cellsSerious conditionIndependent cohortCancer InstituteKb heterozygous deletionSmall sample sizePilot genome-wide association studyGenetic polymorphismsSingle nucleotide polymorphisms
2001
Immunologic recovery after autologous blood stem cell transplantation in patients with AL-amyloidosis
Akpek G, Lenz G, Lee S, Sanchorawala V, Wright D, Colarusso T, Waraska K, Lerner A, Vosburgh E, Skinner M, Comenzo R. Immunologic recovery after autologous blood stem cell transplantation in patients with AL-amyloidosis. Bone Marrow Transplantation 2001, 28: 1105-1109. PMID: 11803350, DOI: 10.1038/sj.bmt.1703298.Peer-Reviewed Original ResearchConceptsStem cell transplantationAutologous blood stem cell transplantationBlood stem cell transplantationAbsolute lymphocyteT cellsImmunoglobulin levelsCell transplantationAL amyloidosisProliferative responsePost-stem cell transplantationT cell proliferative responsesNumber of CD4Post-transplant immunosuppressionCellular immune functionSerum immunoglobulin levelsT-cell immunosuppressionCell proliferative responsesT cell proliferationB cell functionInitial study groupImmunologic recoveryLymphoid recoveryPCP pneumoniaCell immunosuppressionLymphocyte subsets
2000
Efficacy of a sucrose‐formulated recombinant factor VIII used for 22 surgical procedures in patients with severe haemophilia A
Scharrer I, Brackmann H, Sultan Y, Abshire T, Gazengel C, Ragni M, Gorina E, Vosburgh E, Kellermann E. Efficacy of a sucrose‐formulated recombinant factor VIII used for 22 surgical procedures in patients with severe haemophilia A. Haemophilia 2000, 6: 614-618. PMID: 11122384, DOI: 10.1046/j.1365-2516.2000.00432.x.Peer-Reviewed Original ResearchSafety and efficacy of solvent/detergent‐treated antihaemophilic factor with an added 80 °C terminal dry heat treatment in patients with haemophilia A
Powell J, Bush M, Harrison J, Abildgaard C, Vosburgh E, Thompson A, Hurst D. Safety and efficacy of solvent/detergent‐treated antihaemophilic factor with an added 80 °C terminal dry heat treatment in patients with haemophilia A. Haemophilia 2000, 6: 140-149. PMID: 10792471, DOI: 10.1046/j.1365-2516.2000.00407.x.Peer-Reviewed Original ResearchConceptsHeat-treated preparationsPlasma-derived factor VIII concentrateCrossover pharmacokinetic studyFactor VIII inhibitorsHome treatment programHemophilia A patientsTerminal dry heat treatmentFactor VIII concentrateViral inactivation processesSolvent/detergent treatmentA patientsFactor VIII preparationsClinical parametersVIII inhibitorsHaemophilia treatmentPatientsHemophilia AVIII concentrateTreatment programRare reportsAntihaemophilic factorPharmacokinetic studyDevelopment of inhibitorsTreatmentNon-enveloped virusesSucrose Formulated Recombinant Human Antihemophilic Factor VIII Is Safe and Efficacious for Treatment of Hemophilia A in Home Therapy
Abshire T, Brackmann H, Scharrer I, Hoots K, Gazengel C, Powell J, Gorina E, Kellermann E, Vosburgh E. Sucrose Formulated Recombinant Human Antihemophilic Factor VIII Is Safe and Efficacious for Treatment of Hemophilia A in Home Therapy. Thrombosis And Haemostasis 2000, 83: 811-816. PMID: 10896230, DOI: 10.1055/s-0037-1613925.Peer-Reviewed Original ResearchConceptsRFVIII-FSHome therapyAdverse eventsPharmacokinetic profileHemophilia ADrug-related adverse eventsRecombinant factor VIII productsIntermittent chest painFactor replacement therapyTreatment of bleedsSevere haemophilia AFirst clinical trialFactor VIII productsExcellent hemostatic controlSignificant adverse effectsFull-length rFVIIIChest painReplacement therapyClinical trialsViral inactivation stepsHemostatic controlExposure daysPatientsFactor VIIITherapy
1999
Intermediate‐dose intravenous melphalan and blood stem cells mobilized with sequential GM+G‐CSF or G‐CSF alone to treat AL (amyloid light chain) amyloidosis
COMENZO R, SANCHORAWALA V, FISHER C, AKPEK G, FARHAT M, CERDA S, BERK J, DEMBER L, FALK R, FINN K, SKINNER M, VOSBURGH E. Intermediate‐dose intravenous melphalan and blood stem cells mobilized with sequential GM+G‐CSF or G‐CSF alone to treat AL (amyloid light chain) amyloidosis. British Journal Of Haematology 1999, 104: 553-559. PMID: 10086794, DOI: 10.1046/j.1365-2141.1999.01216.x.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAmyloidosisAntineoplastic Agents, AlkylatingDrug CombinationsFemaleGranulocyte Colony-Stimulating FactorGranulocyte-Macrophage Colony-Stimulating FactorHematopoietic Stem Cell MobilizationHematopoietic Stem Cell TransplantationHumansInfusions, IntravenousLeukapheresisMaleMelphalanMiddle AgedSurvival AnalysisConceptsBlood stem cellsMobilization regimensG-CSFIntermediate dose (15-30 mg/m2, day 1) intravenous melphalanDose-intensive melphalanPhase 11 trialGrade 4 toxicityComplete haematological responseCells/AL amyloidosis patientsTerms of CD34Stem cellsActive regimenMobilization patientsDose melphalanOrgan involvementIntravenous melphalanCardiac amyloidD mortalityMonths 57AL amyloidosisAmyloidosis patientsHaematological responsePatientsDay 5
1998
Dose-Intensive Melphalan With Blood Stem-Cell Support for the Treatment of AL (Amyloid Light-Chain) Amyloidosis: Survival and Responses in 25 Patients
Comenzo R, Vosburgh E, Falk R, Sanchorawala V, Reisinger J, Dubrey S, Dember L, Berk J, Akpek G, LaValley M, O'Hara C, Arkin C, Wright D, Skinner M. Dose-Intensive Melphalan With Blood Stem-Cell Support for the Treatment of AL (Amyloid Light-Chain) Amyloidosis: Survival and Responses in 25 Patients. Blood 1998, 91: 3662-3670. PMID: 9573002, DOI: 10.1182/blood.v91.10.3662.Peer-Reviewed Original ResearchMeSH KeywordsAdultAmyloidosisAntineoplastic Agents, AlkylatingCohort StudiesCombined Modality TherapyErythrocyte TransfusionFemaleHematopoietic Stem Cell TransplantationHumansKidneyLife TablesLiverMaleMelphalanMiddle AgedMyocardiumNervous SystemParaproteinsPlatelet TransfusionPrognosisRecurrenceSeverity of Illness IndexSurvival AnalysisTransplantation ConditioningTreatment OutcomeConceptsClonal plasma cell disorderPlasma cell disordersAL amyloidosisCell disordersPerformance statusComplete responseOrgan involvementAutologous stem cell transplantationBlood stem cell supportSignificant negative prognostic factorOrgan systemsDose-intensive melphalanDose-intensive therapyMedian performance statusPredominant cardiac involvementPerformance status 1Year of diagnosisGranulocyte-colony stimulating factorNegative prognostic factorStem cell supportBiopsy-proven amyloidosisProgressive organ failureStem cell transplantationMajor organ systemsPrior therapy
1996
Dose-Intensive Melphalan With Blood Stem Cell Support for the Treatment of AL Amyloidosis: One-Year Follow-up in Five Patients
Comenzo R, Vosburgh E, Simms R, Bergethon P, Sarnacki D, Finn K, Dubrey S, Faller D, Wright D, Falk R, Skinner M. Dose-Intensive Melphalan With Blood Stem Cell Support for the Treatment of AL Amyloidosis: One-Year Follow-up in Five Patients. Blood 1996, 88: 2801-2806. PMID: 8839879, DOI: 10.1182/blood.v88.7.2801.bloodjournal8872801.Peer-Reviewed Original ResearchMeSH KeywordsAdultAmyloidosisCardiomyopathiesFeasibility StudiesFemaleFollow-Up StudiesGastrointestinal DiseasesGranulocyte Colony-Stimulating FactorHematopoietic Stem Cell TransplantationHepatomegalyHumansKarnofsky Performance StatusMaleMelphalanMiddle AgedNephrotic SyndromeNeutropeniaPeripheral Nervous System DiseasesPrednisoneRemission InductionTreatment OutcomeConceptsBlood stem cell supportStem cell supportPlasma cell dyscrasiaDose-intensive melphalanPerformance statusAL amyloidosisCell dyscrasiaCell supportClinical remissionIntravenous melphalanBone marrow biopsy specimensDose-intensive chemotherapyFibrillar amyloid proteinsImproved performance statusMedian performance statusSurvival of patientsTime of diagnosisReversal of symptomsBlood stem cellsClonal plasma cellsOne-year followOrgan-specific diseasesMarrow biopsy specimensForm of treatmentDaily proteinuriaTiazofurin effects on IMP-dehydrogenase activity and expression in the leukemia cells of patients with CML blast crisis.
Wright D, Boosalis M, Waraska K, Oshry L, Weintraub L, Vosburgh E. Tiazofurin effects on IMP-dehydrogenase activity and expression in the leukemia cells of patients with CML blast crisis. Anticancer Research 1996, 16: 3349-51. PMID: 9042310.Peer-Reviewed Original ResearchConceptsLeukemic blastsBlast crisisMRNA expressionCML-BC patientsPhase II trialBlood of patientsCycle-active agentsChronic myelogenous leukemiaDays of treatmentCML blast crisisHematologic remissionII trialTrial patientsHematologic responseTiazofurin treatmentWBC countIMP dehydrogenase activityCML-BCPartial clearanceMyelogenous leukemiaLeukemic clonePatientsNeoplastic cellsSequential coursesProliferative activity
1995
Collection of mobilized blood progenitor cells for hematopoietic rescue by large‐volume leukapheresis
Comenzo R, Vosburgh E, Weintraub L, Tansan S, Arkin C, Wright D. Collection of mobilized blood progenitor cells for hematopoietic rescue by large‐volume leukapheresis. Transfusion 1995, 35: 493-497. PMID: 7770900, DOI: 10.1046/j.1537-2995.1995.35695288768.x.Peer-Reviewed Original ResearchConceptsBlood progenitor cellsDose-intensive chemotherapyRapid hematopoietic reconstitutionMononuclear cellsLarge-volume leukapheresisClonogenic progenitor cellsLVL proceduresProgenitor cellsHematopoietic rescueHematopoietic reconstitutionColony-stimulating factor administrationCFU-GMAutologous hematopoietic rescuePercent of patientsHigh-dose chemotherapyProgenitor cell collectionColony-stimulating factorLimited chemotherapyPatient weightCancer patientsFactor administrationPlatelet recoveryTarget dosesChemotherapyPatients
1993
Chronic Tension Pneumothorax Mimicking Tension Bullae Use of Video-Assisted Thoracoscopy for Diagnosis
Kupferschmid J, Carr T, Fonger J, Aldea G, Vosburgh E. Chronic Tension Pneumothorax Mimicking Tension Bullae Use of Video-Assisted Thoracoscopy for Diagnosis. CHEST Journal 1993, 104: 1913-1914. PMID: 8252987, DOI: 10.1378/chest.104.6.1913.Peer-Reviewed Original ResearchRational intervention in von Willebrand's disease.
Vosburgh E. Rational intervention in von Willebrand's disease. Hospital Practice 1993, 28: 31-41, 45-8. PMID: 8450003, DOI: 10.1080/21548331.1993.11442899.Peer-Reviewed Educational Materials
1992
Excessive Fibrinolysis in Amyloidosis Associated with Elevated Plasma Single-Chain Urokinase
Liebman H, Carfagno M, Weitz I, Berard P, Diiorio J, Vosburgh E, Simms R. Excessive Fibrinolysis in Amyloidosis Associated with Elevated Plasma Single-Chain Urokinase. American Journal Of Clinical Pathology 1992, 98: 534-541. PMID: 1485607, DOI: 10.1093/ajcp/98.5.534.Peer-Reviewed Original ResearchConceptsExcessive fibrinolysisPatient plasmaDepressed plasma concentrationsActivator activityTissue plasminogen activatorPlasminogen activator inhibitorAlpha-2-plasmin inhibitorCoagulation factor XIIResults of immunoprecipitationEpsilon-aminocaproic acidSevere bleedingPrimary amyloidosisHemostatic disordersPlasma concentrationsAmyloidosis resultsUrokinase-type activatorAmyloidosis AssociatedAntigenic concentrationActivator inhibitorFactor VIIIFibrinolysisFactor XIIPatientsSingle-chain urokinasePlasminogen activatorPruritus secondary to hydroxyurea therapy in a woman with polycythemia vera
Vosburgh E. Pruritus secondary to hydroxyurea therapy in a woman with polycythemia vera. American Journal Of Hematology 1992, 41: 70-70. PMID: 1503109, DOI: 10.1002/ajh.2830410120.Commentaries, Editorials and LettersPulmonary leukostasis secondary to all-trans retinoic acid in the treatment of acute promyelocytic leukemia in first relapse.
Vosburgh E. Pulmonary leukostasis secondary to all-trans retinoic acid in the treatment of acute promyelocytic leukemia in first relapse. Leukemia 1992, 6: 608-10. PMID: 1602800.Peer-Reviewed Case Reports and Technical NotesConceptsPulmonary leukostasisComplete remissionFirst relapseStandard induction chemotherapyRetinoic acid syndromeRetinoic acidAcute promyelocytic leukemiaAcute promyelocytic leukemia cellsTrans retinoic acidInduction chemotherapyResistant diseaseSignificant leukocytosisClinical trialsLeukostasisPromyelocytic leukemiaPromyelocytic leukemia cellsMature neutrophilsPatientsLeukemia cellsRelapseHigh rateOverall toxicityDe novoRemissionLeukocytosis
1991
Report of a variant t(1;15;17)(p36;q22;q21.1) in a patient with acute promyelocytic leukemia
Osella P, Wyandt H, Vosburgh E, Milunsky A. Report of a variant t(1;15;17)(p36;q22;q21.1) in a patient with acute promyelocytic leukemia. Cancer Genetics 1991, 57: 201-207. PMID: 1756499, DOI: 10.1016/0165-4608(91)90153-l.Peer-Reviewed Case Reports and Technical Notes